The Biologics Price Competition and Innovation Act, signed into law under the Patient Protection and Affordable Care Act in 2010, creates an abbreviated approval pathway for biologic products ...

Biosimilars offer the potential to deliver substantial cost savings in biologic therapy and to contribute to increased patient access to biologic treatments, both of which are particularly relevant ...

Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...

Biosimilars are gaining traction as competitors aim to capture market share from branded biologics such as Humira and Neulasta. Humira now faces competition from seven biosimilars, while Neulasta has ...

When prescribing a biologic treatment, physicians have the opportunity to share what alternatives might be available to best suit their patient’s lifestyle, including affordability. (1) (Cedric ...

Biologics are medications made using living organisms. Biosimilars are FDA-approved biologic products that are highly similar to an existing biologic (the reference drug). Biologic and biosimilar ...

The incidence of inflammatory bowel disease (IBD) has increased globally, 1 which has redirected the health care system’s focus toward safe and affordable pharmacologic interventions. As the patents ...

Biosimilar drugs (also known as biosimilars, or follow-on biologics) are almost identical versions of a medical product or a drug that are produced by a different company to the parent company. They ...

Please provide your email address to receive an email when new articles are posted on . The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in ...

Fact: branded biologic drugs are consistently among the most expensive in our healthcare system. 1 Compounding this, chronic conditions – often treated with biologics – are becoming increasingly ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Biosimilars are gradually making inroads in the outpatient drug ...

Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America In total, 95% of respondents could identify the most appropriate definition of ...